Gaining a Pulse on Formulation and Drug Delivery Challenges and Technologies - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Gaining a Pulse on Formulation and Drug Delivery Challenges and Technologies
A recent survey examines the industry's views on the chief challenges and technologies in drug delivery and formulation development.

Pharmaceutical Technology
Volume 36, Issue 4

Seeking solutions

In addressing problems of bioavailability and solubility, "there are two dimensions to which to address solubility of poorly soluble drugs, the drug substance and drug product," says Kurt Nielsen, PhD and senior vice-president, innovation and growth with Catalent Pharma Solutions, in commenting on the survey results. With respect to the drug substance, he points to various solutions, such as optimizing the salt form or solid-state form (i.e., polymorph or co-crystal). Slight modifications to the drug substance also can be made to improve solubility, such as converting the drug to a prodrug, or by reducing the particle size of the drug substance, explains Nielsen.

With respect to the drug product, Nielsen says that various methods can improve solubility, ranging from straightforward strategies, such as solubilizing agents (e.g., surfactants and polymers) to more complex solutions where site-specific drug release is required to address such issues as poor stability of the drug in the stomach or pre-systematic metabolism in certain locations in the gastrointestinal tract. As with the drug substance, particle engineering can be used to not only optimize solubility but also to modify or control the release of the drug, he adds. In sum, these strategies seek to address the key aspects of solubility, permeability, and site of absorption.

On a dosage form level, various approaches may be used. "Liquid-based dosage forms, such as softgels, dispersion-based dosage forms through hot-melt or spray-dried dispersions, and drug layering and coating can be used to improve solubility and bioavailability of oral dosage forms," says Nielsen. If bioavailability is still a problem, other routes of administration, such as transdermal, buccal, and sublingual drug delivery can be considered.


1. Catalent–Pharmaceutical Technology Landscape Drug Delivery Survey (December 2011).


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here